Engineering and design of chimeric antigen receptors
T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new
class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since …
class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since …
Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies
X Xu, Q Sun, X Liang, Z Chen, X Zhang… - Frontiers in …, 2019 - frontiersin.org
Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell
acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic …
acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic …
Engineered T cells: the promise and challenges of cancer immunotherapy
The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …
cancer is derived from our own cells, immune responses to dysregulated cell growth present …
[HTML][HTML] Global manufacturing of CAR T cell therapy
BL Levine, J Miskin, K Wonnacott, C Keir - Molecular therapy Methods & …, 2017 - cell.com
Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high
response rates in patients with B cell malignancies, and chimeric antigen receptor T cell …
response rates in patients with B cell malignancies, and chimeric antigen receptor T cell …
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells
KP Micklethwaite, K Gowrishankar… - Blood, The Journal …, 2021 - ashpublications.org
We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-
derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that …
derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that …
A guide to manufacturing CAR T cell therapies
P Vormittag, R Gunn, S Ghorashian… - Current opinion in …, 2018 - Elsevier
Highlights•CAR T cell clinical trial manufacturing data is investigated.•Three dominant
process routes are uncovered.•The trend in CAR T cell manufacturing is towards …
process routes are uncovered.•The trend in CAR T cell manufacturing is towards …
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
P Kebriaei, H Singh, MH Huls… - The Journal of …, 2016 - Am Soc Clin Investig
BACKGROUND. T cells expressing antigen-specific chimeric antigen receptors (CARs)
improve outcomes for CD19-expressing B cell malignancies. We evaluated a human …
improve outcomes for CD19-expressing B cell malignancies. We evaluated a human …
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
LV Hurton, H Singh, AM Najjar… - Proceedings of the …, 2016 - National Acad Sciences
Adoptive immunotherapy retargeting T cells to CD19 via a chimeric antigen receptor (CAR)
is an investigational treatment capable of inducing complete tumor regression of B-cell …
is an investigational treatment capable of inducing complete tumor regression of B-cell …
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
T cells redirected to specific antigen targets with engineered chimeric antigen receptors
(CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR …
(CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR …
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
S Su, B Hu, J Shao, B Shen, J Du, Y Du, J Zhou, L Yu… - Scientific reports, 2016 - nature.com
Strategies that enhance the function of T cells are critical for immunotherapy. One negative
regulator of T-cell activity is ligand PD-L1, which is expressed on dentritic cells (DCs) or …
regulator of T-cell activity is ligand PD-L1, which is expressed on dentritic cells (DCs) or …